{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:38:18Z","timestamp":1775561898816,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009882","name":"Regione Lombardia","doi-asserted-by":"publisher","award":["Risposta immune in pazienti con COVID-19 e co-morbidit\u00e0"],"award-info":[{"award-number":["Risposta immune in pazienti con COVID-19 e co-morbidit\u00e0"]}],"id":[{"id":"10.13039\/501100009882","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Division of Intramural Research of the National Institute of Allergy and Infectious Diseases and the National Institute of Dental and Craniofacial Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphoproliferative disorders (CLD), multiple myeloma (MM), or myelodysplastic\/myeloproliferative syndromes (MDS\/MPN). Antibody (Ab) levels to the SARS-CoV-2 nucleocapsid (N) and spike (S) protein were measured at +1, +3, +6 months after nasal swabs became PCR-negative. Forty-five patients (9 FL, 8 DLBCL, 8 CLD, 10 MM, 10 MDS\/MPS) and 18 controls were studied. Mean anti-N and anti-S-Ab levels were similar between HM patients and controls, and shared the same behavior, with anti-N Ab levels declining at +6 months and anti-S-Ab remaining stable. Seroconversion rates were lower in HM patients than in controls. In lymphoma patients mean Ab levels and seroconversion rates were lower than in other HM patients, primarily because all nine patients who had received rituximab within 6 months before COVID-19 failed to produce anti-N and anti-S-Ab. Only one patient requiring hematological treatment after COVID-19 lost seropositivity after 6 months. No reinfections were observed. These results may inform vaccination policies and clinical management of HM patients.<\/jats:p>","DOI":"10.1038\/s41408-021-00546-9","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T11:03:20Z","timestamp":1631617400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-3237","authenticated-orcid":false,"given":"C.","family":"Cattaneo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Cancelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2075-8391","authenticated-orcid":false,"given":"L.","family":"Imberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-3137","authenticated-orcid":false,"given":"K.","family":"Dobbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sottini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-3127","authenticated-orcid":false,"given":"A.","family":"Belotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Anastasia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8858-3236","authenticated-orcid":false,"given":"V.","family":"Quaresima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3052-7463","authenticated-orcid":false,"given":"A.","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Chiorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. C.","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. I.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. D.","family":"Burbelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. D.","family":"Notarangelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"546_CR1","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737\u201345.","journal-title":"Lancet Haematol"},{"key":"546_CR2","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1002\/cncr.33160","volume":"126","author":"C Cattaneo","year":"2020","unstructured":"Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E, et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer. 2020;126:5069\u201376.","journal-title":"Cancer"},{"key":"546_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","volume":"13","author":"J Garc\u00eda-Su\u00e1rez","year":"2020","unstructured":"Garc\u00eda-Su\u00e1rez J, de la Cruz J, Cedillo \u00c1, Llamas P, Duarte R, Jim\u00e9nez-Yuste V, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol 2020;13:133.","journal-title":"J Hematol Oncol"},{"key":"546_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/bjh.17027","volume":"191","author":"TA Fox","year":"2020","unstructured":"Fox TA, Troy-Barnes E, Kirkwood AA, Chan WY, Day JW, Chavda SJ, et al. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy. Br J Haematol 2020;191:194\u2013206.","journal-title":"Br J Haematol"},{"key":"546_CR5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N. Engl J Med 2007;357:1903\u201315.","journal-title":"N. Engl J Med"},{"key":"546_CR6","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","volume":"5","author":"J Seow","year":"2020","unstructured":"Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel K, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 2020;5:1598\u2013607.","journal-title":"Nat Microbiol"},{"key":"546_CR7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/cid\/ciab004","volume":"73","author":"SF Lumley","year":"2021","unstructured":"Lumley SF, Wei J, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin Infect Dis. 2021;73:699.","journal-title":"Clin Infect Dis"},{"key":"546_CR8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1126\/science.abd7728","volume":"370","author":"A Wajnberg","year":"2020","unstructured":"Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370:1227\u201330.","journal-title":"Science"},{"key":"546_CR9","doi-asserted-by":"crossref","unstructured":"Dan, JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to eight months after infection. Science 2021: 371, eabf4063.","DOI":"10.1126\/science.abf4063"},{"key":"546_CR10","doi-asserted-by":"publisher","unstructured":"De Giorgi, V, West KA, Henning AN, Chen L, Holbrook MR, Gross R, et al. Anti-SARS-CoV-2 serology persistence over time in COVID-19 convalescent plasma donors. medRxiv. https:\/\/doi.org\/10.1101\/2021.03.08.21253093 (2021).","DOI":"10.1101\/2021.03.08.21253093"},{"key":"546_CR11","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00238-5","volume":"397","author":"Z He","year":"2021","unstructured":"He Z, Ren L, Yang J, Guo L, Feng L, Ma C, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet. 2021;397:1075\u201384.","journal-title":"Lancet"},{"key":"546_CR12","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/microorganisms9030556","volume":"9","author":"J Favresse","year":"2021","unstructured":"Favresse J, Eucher C, Elsen M, Gillot C, Van Eeckhoudt S, Dogn\u00e9 JM, et al. Persistence of anti-SARS-CoV-2 antibodies depends on the analytical kit: a report for up to 10 months after infection. Microorganisms. 2021;9:556.","journal-title":"Microorganisms"},{"key":"546_CR13","doi-asserted-by":"publisher","first-page":"e1306","DOI":"10.1002\/cti2.1306","volume":"10","author":"JT Sandberg","year":"2021","unstructured":"Sandberg JT, Varnait\u0117 R, Christ W, Chen P, Muvva JR, Maleki KT, et al. SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of disease severity at hospitalization. Clin Transl Immunol. 2021;10:e1306.","journal-title":"Clin Transl Immunol"},{"key":"546_CR14","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3324\/haematol.2020.269878","volume":"106","author":"C Maia","year":"2020","unstructured":"Maia C, Mart\u00edn-S\u00e1nchez E, Garc\u00e9s JJ, De Cerio AL, Inog\u00e9s S, Landecho MF, et al. Immunologic characterization of COVID-19 patients with hematological cancer. Haematologica. 2020;106:1457\u201360.","journal-title":"Haematologica"},{"key":"546_CR15","doi-asserted-by":"publisher","unstructured":"Huang, A, Bange E, Han N, Wileyto EP, Kim J, Gouma S, et al. CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-162289\/v1 (2021).","DOI":"10.21203\/rs.3.rs-162289\/v1"},{"key":"546_CR16","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1038\/s41375-020-01030-2","volume":"34","author":"LE Roeker","year":"2020","unstructured":"Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34:3047\u20139.","journal-title":"Leukemia"},{"key":"546_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/infdis\/jiaa273","volume":"222","author":"PD Burbelo","year":"2020","unstructured":"Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, et al. Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. J Infect Dis 2020;222:206\u201313.","journal-title":"J Infect Dis"},{"key":"546_CR18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1097\/CM9.0000000000000899","volume":"133","author":"JM Qu","year":"2020","unstructured":"Qu JM, Wang C, Cao B, on behalf of Chinese Thoracic Society and Chinese Association of Chest Physicians. Guidance for the management of adult patients with coronavirus disease 2019. Chin Med J 2020;133:1575\u201394.","journal-title":"Chin Med J"},{"key":"546_CR19","first-page":"100734","volume":"32","author":"S Yamayoshi","year":"2021","unstructured":"Yamayoshi S, Yasuhara A, Ito M, Akasaka O, Nakamura M, Nakachi I, et al. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. E Clinical Medicine. 2021;32:100734.","journal-title":"E Clinical Medicine"},{"key":"546_CR20","doi-asserted-by":"publisher","unstructured":"Crawford, KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiaa618 (2020).","DOI":"10.1093\/infdis\/jiaa618"},{"key":"546_CR21","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/j.1469-0691.2004.01009.x","volume":"10","author":"PR Hsueh","year":"2004","unstructured":"Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect 2004;10:1062\u20136.","journal-title":"Clin Microbiol Infect"},{"key":"546_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;26:845\u20138.","journal-title":"Nat Med"},{"key":"546_CR23","doi-asserted-by":"publisher","first-page":"2000763","DOI":"10.1183\/13993003.00763-2020","volume":"56","author":"B Lou","year":"2020","unstructured":"Lou B, Li TD, Zheng SF, Su YY, Li ZY, Liu W, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. Eur Respir J 2020;56:2000763.","journal-title":"Eur Respir J"},{"key":"546_CR24","doi-asserted-by":"publisher","unstructured":"Peluso, MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. medRxiv. https:\/\/doi.org\/10.1101\/2021.03.03.21251639 (2021).","DOI":"10.1101\/2021.03.03.21251639"},{"key":"546_CR25","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","volume":"383","author":"DF Gudbjartsson","year":"2020","unstructured":"Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune response to SARS-CoV-2 in Iceland. N. Engl J Med 2020;383:1724\u201334.","journal-title":"N. Engl J Med"},{"key":"546_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41375-020-01103-2","volume":"35","author":"J O'nions","year":"2021","unstructured":"O'nions J, Muir L, Zheng J, Rees-Spear C, Rosa A, Roustan C, et al. SARS-CoV-2 antibody responses in patients with acute leukaemia. Leukemia. 2021;35:289\u201392.","journal-title":"Leukemia"},{"key":"546_CR27","doi-asserted-by":"publisher","unstructured":"Bird, PW, Badhwar, V, Kennedy, B, Ladani, S & Tang, JW. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.26886 (2021).","DOI":"10.1002\/jmv.26886"},{"key":"546_CR28","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.7150\/jca.53863","volume":"12","author":"W Liu","year":"2021","unstructured":"Liu W, Li Z, He W, Yu D, Wang P, Cai L, et al. Impact of chemotherapy on lymphocytes and serological memory in recovered COVID-19 patients with acute leukemia. J Cancer 2021;12:2450\u20135.","journal-title":"J Cancer"},{"key":"546_CR29","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1111\/cas.14544","volume":"111","author":"X Zhou","year":"2020","unstructured":"Zhou X, Wang G, Chen L, Meng F, Huang L, Huang L, et al. Clinical characteristics of hematological patients concomitant with COVID-19. Cancer Sci 2020;111:3379\u201385.","journal-title":"Cancer Sci"},{"key":"546_CR30","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1002\/jmv.26103","volume":"92","author":"A Carmo","year":"2020","unstructured":"Carmo A, Pereira-Vaz J, Mota V, Mendes A, Morais C, da Silva AC, et al. Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19. J Med Virol 2020;92:2227\u201331.","journal-title":"J Med Virol"},{"key":"546_CR31","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/blood.2020008423","volume":"136","author":"T Hueso","year":"2020","unstructured":"Hueso T, Pouderoux C, P\u00e9r\u00e9 H, Beaumont AL, Raillon LA, Ader F, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136:2290\u20135.","journal-title":"Blood"},{"key":"546_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","volume":"146","author":"I Quinti","year":"2020","unstructured":"Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol 2020;146:211\u201313.e4.","journal-title":"J Allergy Clin Immunol"},{"key":"546_CR33","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","volume":"147","author":"I Meyts","year":"2021","unstructured":"Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol 2021;147:520\u201331.","journal-title":"J Allergy Clin Immunol"},{"key":"546_CR34","doi-asserted-by":"publisher","first-page":"e240765","DOI":"10.1136\/bcr-2020-240765","volume":"14","author":"SY Loh","year":"2021","unstructured":"Loh SY, Bassett J, Hoodless EJ, Walshaw M. Possible COVID-19 reinfection in a patient with X-linked agammaglobulinaemia. BMJ Case Rep. 2021;14:e240765.","journal-title":"BMJ Case Rep."},{"key":"546_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2352-3026(21)00110-1","volume":"8","author":"S Bird","year":"2021","unstructured":"Bird S, Panopoulou A, Shea RL, Tsui M, Saso R, Sud A, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021;8:389.","journal-title":"Lancet Haematol"},{"key":"546_CR36","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Y Herishanu","year":"2021","unstructured":"Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165\u201373.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00546-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00546-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00546-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:22:56Z","timestamp":1669918976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00546-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["546"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00546-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases and the National Institute of Dental and Craniofacial Research. The study was supported by a grant from Regione Lombardia, Italy (project \u201cRisposta immune in pazienti con COVID-19 e co-morbidit\u00e0\u201d).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}